Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

scientific article published on 22 June 2018

Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2018.06.021
P698PubMed publication ID29941327

P50authorJulia DrylewiczQ56809902
Marije P HennusQ114258327
Louis J BontQ114259431
P2093author name stringCornelis K van der Ent
José A M Borghans
Kentigern Thorburn
Nienke M Scheltema
Job B van Woensel
Xynthia M Kavelaars
P2860cites workRisk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysisQ26774885
Maternal immunizationQ26853746
IgG placental transfer in healthy and pathological pregnanciesQ27025979
The level and duration of RSV-specific maternal IgG in infants in Kilifi KenyaQ30941156
The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidityQ33574734
Pertussis Antibody Transfer to Preterm Neonates After Second- Versus Third-Trimester Maternal ImmunizationQ33712033
Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.Q33712986
The burden of respiratory syncytial virus infection in young childrenQ34938343
Respiratory syncytial virus-associated intensive care unit admission in children in Southern ChinaQ35037404
Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in BangladeshQ35102554
Lower transplacental antibody transport for measles, mumps, rubella and varicella zoster in very preterm infantsQ35146973
Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal KenyaQ35223733
Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infectionQ35347139
Mortality in children from influenza and respiratory syncytial virusQ35559491
Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal KenyaQ36194104
Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction.Q37410332
Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy childrenQ37776266
Transplacental transport of IgG antibodies to preterm infants: a review of the literatureQ37814668
Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization: Secondary Analysis of a Randomized Clinical TrialQ38390492
Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in EnglandQ38621552
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling studyQ38687853
Pertussis and influenza immunisation during pregnancy: a landscape reviewQ38691984
Intensive Care Unit Admission and Death Rates of Infants Admitted With Respiratory Syncytial Virus Lower Respiratory Tract Infection in MexicoQ39700756
Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case seriesQ40040542
Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural NepalQ40043300
Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, BelgiumQ40485629
Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant womenQ40555244
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.Q41060727
Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigsQ41441320
Potential impact of a maternal vaccine for RSV: A mathematical modelling study.Q41926872
WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.Q45341636
Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infectionQ45392619
The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus diseaseQ45397091
Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.Q45739727
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virusQ45759631
The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study.Q53084808
Kinetics of the Antibody Response to Tetanus-Diphtheria-Acellular Pertussis Vaccine in Women of Childbearing Age and Postpartum WomenQ57793146
Evolution of maternofetal transport of immunoglobulins during human pregnancyQ71860864
P433issue31
P407language of work or nameEnglishQ1860
P921main subjectinfancy stageQ49257364
P304page(s)4693-4700
P577publication date2018-06-22
P1433published inVaccineQ7907941
P1476titlePotential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy
P478volume36